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AbstrAct
There is increasing interest in inhibitors targeting BET (bromodomain and extra-
terminal) proteins because of the association between this family of proteins and 
cancer progression. BET inhibitors were initially shown to have efficacy in hematologic 
malignancies; however, a number of studies have now shown that BET inhibitors 
can also block progression of non-hematologic malignancies. In this Review, we 
summarize the efficacy of BET inhibitors in select solid tumors; evaluate the role of BET 
proteins in mediating resistance to current targeted therapies; and consider potential 
toxicities of BET inhibitors. We also evaluate recently characterized mechanisms of 
resistance to BET inhibitors; summarize ongoing clinical trials with these inhibitors; 
and discuss potential future roles of BET inhibitors in patients with solid tumors.
IntroductIon
Epigenetic changes that occur during cancer 
progression are increasingly recognized as a potential 
target for therapeutic intervention. Bromodomains 
(BRDs) are evolutionarily conserved protein interaction 
modules that bind to acetylation motifs present in histones 
and enable recruitment of transcription factors and other 
chromatin regulators during the precise sequence of 
events involved with RNA transcription [1, 2]. The BET 
(BRD and extra-terminal) family of proteins regulates the 
transcription of genes involved in several human diseases 
and includes family members BRD2, BRD3, BRD4, and 
the testis-specific BRDT [1, 2]. Significantly, BRD4 has 
been established as a key regulator of transcriptional 
elongation by recruiting the positive transcription 
elongation factor b (P-TEFb) complex to chromatin [3, 4]. 
BRD4 also mediates the formation of the active form of 
P-TEFb, which in turn phosphorylates and activates RNA 
polymerase II (RNA Pol II; Figure 1). BRD4 is enriched 
in large numbers of enhancer regions, and also in some 
large super-enhancer regions, and mediates expression of 
key transcription factors important for cancer development 
and progression [5]. BET inhibition displaces BRD4 
from these super-enhancers and blocks expression of 
certain key oncogenes, such as MYC [5]. Besides binding 
histones, BRD proteins can also regulate cellular function 
by binding to a number of other proteins (Table 1) [1, 2, 
6-11]. 
Significantly, a number of selective and potent 
small-molecule inhibitors have been developed that can 
compete with the acetyl-binding pockets present in the 
bromodomains of BET proteins and block gene expression 
(Figure 2) [1, 2]. These compounds were initially shown 
to be effective in the treatment of leukemia, lymphoma, 
and multiple myeloma, primarily as a result of repressing 
c-MYC expression [1, 12, 13]. Further investigation has 
now shown that BET inhibitors can repress expression 
of oncogenic transcription factors beyond c-MYC, thus 
expanding their potential clinical utility to include solid 
tumors [14-16]. Interested readers are referred to recent 
Reviews for additional details on the mechanisms by 
which BET proteins regulate gene transcription [3, 4, 17]. 
In this Review, we outline the efficacy of BET inhibitors 
in select solid tumors; summarize the role of BET proteins 
in mediating resistance to current targeted therapies; and 
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consider potential toxicities of BET inhibitors. We also 
evaluate recently characterized mechanisms of resistance 
to BET inhibitors; summarize ongoing clinical trials with 
these inhibitors; and discuss potential future roles of BET 
inhibitors in patients with solid tumors.
treAtment of select solId 
tumors wIth bet InhIbItors
bet inhibitors and nut midline carcinoma
Human BRD4 was initially identified because of 
its role in NUT midline carcinoma (NMC) [18, 19], a 
rare subtype of squamous cell carcinoma characterized 
by a translocation most often involving the NUT gene 
and BRD4 [20]. Other potential translocation partners 
also include BRD3 [18, 19]. NMC typically arises from 
the midline structures of the head, neck, and thorax, and 
can be diagnosed in both pediatric and adult patients 
[20]. The disease is extremely aggressive with both 
locoregional and distant spread, and median overall 
survival (OS) was reported at 6.7 months in one large 
series [20]. Mechanistically, the BRD4-NUT fusion 
protein blocks differentiation of NMC cells partly 
through expression of c-MYC [21]. Treatment of NMC 
cells with BET inhibitors results in proliferation arrest 
and squamous cell differentiation in vitro and in mouse 
xenograft models [2], suggesting that BET inhibitors may 
table 1: Interactions of bet proteins with other proteins
Protein effect of interaction references
Acetylated Histones Regulate gene expression (e.g., MYC) [1, 2]
P-TEFb Dissociate HEXIM1 to activate P-TEFb [6]
Cyclin-T1 Stabilize BRD4/P-TEFb complex to enable activation of P-TEFb-responsive genes [6]
RelA Prevent degradation of RelA to maintain active form of NF-κB [7]
TWIST Regulate WNT5A expression to promote invasion, cancer stem cell-like properties and tumorigenesis [8]
GATA1 Promote chromatin occupancy at erythroid target genes to regulate erythroid maturation [9]
Androgen Receptor (AR) Transcriptional regulation of AR target genes [10]
WHSC1 Regulate ERα expression and function [11]
table 2: clinical trials of bet inhibitors in solid tumors
drug cancer Phase trial (accessed clinicaltrials.gov on 02/10/2106)
BAY1238097 Advanced solid tumors
1
(ongoing, but
not recruiting)
NCT02369029
BMS-986158
+/- Paclitaxel
OvC, SCLC, 
TNBC
1/2
(recruiting) NCT02419417
GSK525762
NMC, SCLC, 
NSCLC, CRC, 
NB, CRPC, 
TNBC, 
ER+ BC
1
(recruiting) NCT01587703
GSK2820151 Advanced solid tumors
1
(not yet open) NCT02630251
INCB054329 Advanced solid tumors
1/2
(recruiting) NCT02431260
OTX015 GBM 1/2(terminated) NCT02296476
OTX105/
MK-8628
NMC, TNBC, 
CRPC, PDAC
NSCLC 
1
(ongoing, but
not recruiting)
NCT02259114
TEN-010 Advanced solid tumors
1
(recruiting) NCT01987362
BC, breast cancer; CRC, colorectal cancer; CRPC, castrate resistant prostate cancer; 
GBM, glioblastoma; NB, neuroblastoma; NMC, nut midline cancer; NSCLC, non-small 
cell lung cancer; OvC, ovarian cancer; PDAC, pancreatic ductal adenocarcinoma; SCLC, 
small cell lung cancer; TNBC, triple negative breast cancer.
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be effective against NMCs with clinical trials actively 
evaluating BET inhibitors in NMC patients (Table 2). 
Significantly, a recent report evaluated anti-tumor activity 
in four advanced NMC patients treated with the oral BET 
inhibitor OTX015/MK-8628 on a compassionate basis, 
and demonstrated rapid tumor regression and symptomatic 
relief in two patients [22]. Significantly, the OS of these 
two patients was 18 and 19 months, much longer than 
the median OS of 6.7 months previously reported for 
advanced NMC patients [20].
bet inhibitors and breast cancer
treatment of tamoxifen-resistant breast cancer
Breast cancer is currently the second leading cause 
of cancer death in women. The 5-year survival for breast 
cancer patients is > 90%, but as the most diagnosed 
cancer in women, a significant number of patients will 
ultimately die of their disease [23]. The estrogen-receptor 
(ER)-positive breast cancers represent ~70% of all breast 
cancers, and the selective ER modulator tamoxifen 
remains a mainstay of treatment for these patients [24]. 
While tamoxifen is effective in reducing recurrence and 
death from breast cancer [25-27], most tumors eventually 
develop tamoxifen resistance even while maintaining 
their reliance on estrogen-mediated signaling [28, 29]. 
Significantly, BET proteins contribute to tamoxifen 
resistance by recruiting WHSC1, a histone H3K6 
methyltransferase, to the ERα gene with inappropriate 
modulation of expression [11]. BET proteins directly 
interact with WHSC1, and knockdown of BET proteins 
decreases ERα expression and downstream signaling 
[11]. Importantly, tamoxifen-resistant cell lines are more 
sensitive than parental cell lines to the BET inhibitor 
JQ1 [11]. JQ1 causes persistent suppression of both ERα 
and c-MYC in tamoxifen-resistant cells, while similar 
treatment in parental cell lines results in re-expression of 
both ERα and c-MYC [11]. JQ1 moderately inhibits tumor 
growth in xenograft mice harboring tamoxifen-resistant 
cells, but JQ1 in combination with fulvestrant, a selective 
ER degrader, has synergistic antitumor activity with 
potent inhibition of tumor cell proliferation in the same 
model system [11]. Furthermore, ERα protein levels are 
significantly down regulated in tumors treated with both 
fulvestrant and JQ1 [11]. 
treatment of everolimus-resistant breast cancer
The mTOR pathway has also been shown to mediate 
resistance to anti-estrogens in women with ER-positive 
breast cancer [30]. Everolimus, an allosteric inhibitor of 
mTOR complex 1, has been approved in combination 
with exemestane for treatment of ER+/Her2- breast 
cancer patients who have progressed on treatment with 
anastrozole or letrozole [31]. This combination increased 
progression-free survival (PFS) compared to exemestane 
alone [31]. However, despite initial efficacy, breast cancer 
cells can develop acquired resistance to everolimus. In one 
long-term estrogen deprivation model, resistance occurred 
through increased c-MYC expression mediated by BRD4 
[32]. Notably, down-regulation of c-MYC using siRNA 
or the BET inhibitor JQ1 restored everolimus sensitivity, 
while a combination of everolimus and JQ1 led to 
figure 1: transcriptional activation by brd4. Binding of BRD4 to acetylated histones recruits the positive transcription elongation 
factor b (P-TEFb) complex to chromatin. BRD4 also mediates activation of P-TEFb, which in turn phosphorylates and activates RNA 
polymerase II (RNA Pol II) to initiate gene transcription. 
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synergistic growth inhibition in 3D Matrigel cultures and 
xenograft models [32]. 
treatment of lapatinib-resistant breast cancer 
The HER2 oncogene is amplified or overexpressed 
in ~25% of breast cancers and serves as the primary 
driver of tumor cell growth in the majority of HER2+ 
tumors [33]. There are several FDA approved agents 
for the treatment of HER2+ breast cancers, including 
monoclonal antibodies and the small molecule inhibitor 
lapatinib [34]. Unfortunately, acquired resistance to 
HER2-directed therapies is a clinical challenge for 
patients with advanced HER2+ disease [35]. Resistance to 
lapatinib can result from upregulation of HER3 and from 
activation of multiple tyrosine kinases [35], suggesting 
that tumor cells can reprogram their signaling kinome to 
overcome the inhibitory effects of lapatinib. Significantly, 
BET inhibitors can suppress the kinome reprogramming 
response seen in lapatinib-treated breast cancer cells [36]. 
JQ1 caused greater suppression in genes upregulated 
by lapatinib than in genes unaffected by or even down 
regulated by lapatinib, suggesting that JQ1 preferentially 
modulates lapatinib-responsive gene expression [36]. 
Furthermore, clonogenic growth assays demonstrated 
that dual treatment with lapatinib and JQ1—but not 
monotherapy with JQ1 alone—blocked the growth of 
lapatinib-resistant cells [36]. 
treatment of triple-negative breast cancer
The triple negative breast cancers (ER-, PR-, and 
HER2-; TNBCs) account for ~20% of breast cancers 
[37, 38]. These tumors are often among the most 
aggressive breast cancers and are treated primarily 
with chemotherapy. In a recent screen of breast cancer 
cell lines, TNBC lines were found to be particularly 
sensitive to BET inhibitors compared to luminal and 
HER2+ breast cancer lines [39]. The BET inhibitor JQ1 
or BRD4 siRNA blocked growth of TNBC cell lines by 
decreasing proliferation and inducing apoptosis and/or 
senescence [39], while similar treatments inhibited tumor 
growth in TNBC mouse xenografts [39]. Mechanistically, 
JQ1 treatment preferentially repressed genes associated 
with super-enhancers [5, 40]. In this setting, JQ1 did 
not consistently repress c-MYC, but treatment with JQ1 
resulted in deregulation of transcriptional pathways 
important for cell survival, proliferation and invasion [39].
figure 2: binding of bet family proteins (brd2, brd3, brd4 and brdt) to acetylated (Ac) histones regulates 
expression of genes that contribute to cancer progression. Small-molecule inhibitors, such as JQ1, compete with the acetyl-
binding pockets present in the bromodomains of BET proteins and block BET-dependent gene expression.
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Overall, emerging evidence suggests that in patients 
with breast cancer, BET inhibitors may be of distinct 
therapeutic benefit in a range of disease subtypes through 
modulating acquired resistance to estrogen blockade in 
ER+ disease; enhancing the known therapeutic benefits of 
mTOR inhibitors; allowing for more durable response in 
combination with lapatinib in patients with HER+ disease; 
and decreasing growth of TNBCs.
bet inhibitors and prostate cancer
Prostate cancer is the most commonly diagnosed 
cancer in men in the US. Significant progress has been 
made in the treatment options for prostate cancer patients, 
but over 27,000 men will die of the disease in 2015 in 
the US alone [23]. The mainstay of treatment of advanced 
prostate cancer involves targeting androgen receptor (AR) 
signaling through one of several different drugs that either 
block androgen production (e.g., abiraterone) or block 
the AR itself (e.g., enzalutamide) [41]. Enzalutamide is 
currently approved by the FDA for the treatment of castrate 
resistant prostate cancer (CRPC) both following and 
prior to docetaxel chemotherapy [42, 43]. Unfortunately, 
durable responses to enzalutamide are limited, so there is 
increasing interest in identifying additional targets for the 
treatment of CRPC. 
BET inhibitors are effective in CRPC through 
targeting of the AR signaling network [10]. JQ1 blocks 
proliferation, induces apoptosis, and represses expression 
of anti-apoptotic factors in AR+ cells while also reducing 
transcription of AR target genes [10], indicating that BET 
proteins are involved in AR-mediated transcriptional 
programs. Significantly, JQ1 reduces recruitment of the 
AR to AR-responsive genes to nearly the same extent as 
the direct AR antagonist enzalutamide [10]. Moreover, 
in mouse studies, JQ1 does not affect normal prostate 
growth or testosterone levels even while decreasing 
growth of CRPC tumors [10]. JQ1 is more effective than 
enzalutamide in blocking tumor growth, and in contrast to 
enzalutamide-treated mice, animals treated with JQ1 do 
not develop liver or bone metastasis [10].
Recently, it was also shown that BET inhibitors 
are effective against CRPC cell lines that have become 
resistant to enzalutamide [44]. JQ1 decreases protein 
levels of AR-variant 7, previously identified as one of 
the major drivers of resistance to androgen-deprivation 
therapy (ADT) [45]. Significantly, BET inhibitors display 
enhanced efficacy when combined with enzalutamide 
in vivo [44]. Together, these studies demonstrate that 
combining BET inhibitors with anti-androgens could 
result in more durable therapeutic responses in patients 
with CRPC by subverting resistance mechanisms to ADT.
bet inhibitors and lung cancer
treatment of non-small cell lung cancer
Lung cancer is the most frequent cause of cancer 
mortality worldwide [46], with non-small cell lung cancer 
(NSCLC) accounting for approximately 85 percent of 
lung cancers in the US [23]. Advanced NSCLC is now 
treated based on genotype, with first-line therapy for a 
growing number of patients now an oral tyrosine kinase 
inhibitor instead of chemotherapy. However, long-term 
durable disease control is not yet reality for the majority 
of advanced NSCLC patients, regardless of genotype, 
because of the challenge of acquired resistance [47]. 
Preclinical studies in a range of lung adenocarcinoma 
cell lines harboring either KRAS or EGFR mutations 
suggest that BET inhibitors may have clinical efficacy 
in the treatment of NSCLC [15]. In these cell lines, JQ1 
treatment led to decreased proliferation, cell cycle arrest, 
and induction of apoptosis mediated by the repression of 
FOSL1, a component of the FOS-JUN transcription factor 
complex [15].  
Perhaps even more significant, JQ1 has also been 
shown to specifically have activity in preclinical models 
of KRAS mutant NSCLC. Although KRAS mutations are 
found in an estimated 30% of lung adenocarcinomas, 
there is not yet an effective targeted therapy for the 
majority of these patients [48]. A murine co-clinical trial 
demonstrated that concurrent mutations in LKB1 or TP53 
may help mediate differential response to concurrent 
chemotherapy and MEK inhibition in these tumors, [49] 
and interestingly, co-expression of mutant LKB1 also 
limits the effectiveness of JQ1 in KRAS models [50]. 
LKB1 encodes a serine-threonine kinase that directly 
phosphorylates and activates AMPK, a central metabolic 
sensor [51]. JQ1 and BRD4 knockdown induces apoptosis 
in KRAS mutant cell lines but not in the presence of 
concurrent LKB1 mutation [50]. Similarly, in a transgenic 
mouse model, JQ1 decreased proliferation of KRAS 
mutant tumors but not of mutant KRAS/LKB1 tumors [50], 
further demonstrating that LKB1 may be a key modulator 
of the efficacy of BET inhibitors in KRAS mutant NSCLC.
treatment of small cell lung cancer
Small cell lung cancer (SCLC) accounts for ~13-
15% of lung cancer cases in the US [52]. SCLC has a 
high recurrence rate even after definitive chemotherapy, 
and the 5 year survival rate for SCLC patients is < 5% 
[52]. In a recent screen of 83 lung tumor cell lines in a 
cell proliferation assay, SCLC lines were found to be 
exquisitely sensitive to BET inhibitors even though 
c-MYC levels were unaffected by JQ1 in the sensitive 
SCLC lines [53]. Instead, JQ1 blocked BRD4 binding 
to the enhancer of achaete-scute homolog-1 (ASCL1), 
thereby decreasing ASCL1 expression levels. ASCL1 
is a transcription factor important for development 
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of neuroendocrine progenitor cells [53]. In addition, 
siRNA targeting ASCL1 also decreased proliferation and 
phenocopied the effects of JQ1 in the sensitive cell lines. 
Significantly, over 50% of human SCLC tumor specimens 
were found to overexpress ASCL1 [53], suggesting that 
human SCLC tumors with increased ASCL1 expression 
may benefit from treatment with BET inhibitors.
bet inhibitors and gastrointestinal cancers
treatment of pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is 
currently the 4th leading cause of cancer-related death in 
the US and is projected to become the 2nd leading cause of 
cancer-related death by 2020 [23, 54]. Current standard-
of-care for advanced PDAC is cytotoxic chemotherapy, 
but the success of current drug therapies is severely limited 
[55, 56]. We have shown that BET inhibitors are effective 
against chemotherapy-resistant PDAC cells, in part 
through repression of HMGA2 [16], a non-histone DNA-
binding nuclear protein involved in chromatin remodeling 
and gene transcription [57, 58]. JQ1 decreased HMGA2 in 
cell lines isolated from mouse models of pancreatic cancer 
[59], while also decreasing growth of mouse cell lines in 
vitro with decreased proliferation and increased apoptosis 
in mouse tumors in vivo [59]. Moreover, JQ1 suppressed 
growth of PDAC tumors in patient-derived xenograft 
(PDX) mouse models [60]. Treated PDX tumors did not 
show consistent changes in c-MYC levels, but expression 
profiling identified CDC25B—a regulator of cell cycle 
progression—to be the major target of JQ1 in this setting 
[60]. Finally, BET inhibitors were found to suppress 
PDAC growth and improve survival in the transgenic KPC 
(Kras/p53) PDAC mouse model [61]. In this model, JQ1 
treatment repressed Myc and attenuated inflammation in 
vivo. JQ1 and siRNA targeting BRD4 both decreased IL-6 
production and inhibited Stat signaling [61], pathways 
previously found to mediate PDAC progression in mouse 
models [62, 63]. Overall, these reports strongly indicate 
that BET inhibitors may be effective against PDAC.
treatment of colon cancer
Colon cancer is currently the 2nd leading cause 
of cancer-related death in the US, and patients with 
advanced colon cancer have a median overall survival 
of approximately 2-3 years based primarily upon 
chemotherapy-based treatment regimens [23, 64]. 
Recently, an array-based CRISPR screen identified 
BRD4 as a driver of proliferation and mediator of de-
differentiation in colon cancer [65]. BRD4 knockdown 
decreased proliferation in vitro and decreased tumor 
growth in xenograft mouse studies [65]. BRD4 knockdown 
also repressed c-MYC in xenograft studies and induced 
differentiation into ‘normal-like’ intestinal epithelium 
[65]. Significantly, a subset of colon cancer cell lines 
with a CpG island methylator phenotype (CIMP) were 
particularly sensitive to JQ1 treatment and to JQ1-induced 
c-MYC repression [65]. Approximately 20% of human 
colon cancer tumors arise through the CIMP pathway, and 
these tumors often have poor outcomes [66]. BET inhibitor 
treatment of CIMP(+) cell lines repressed expression of 
colon cancer-associated transcript 1 (CCAT1), a long 
non-coding RNA known to be transcribed off the c-MYC 
superenhancer in colon cancer [65]. Interestingly, CCAT1 
expression also predicted for JQ1 sensitivity not only in 
colon cancer cell lines, but also in lung and pancreatic 
cancer cell lines [65].
treatment of hepatocellular cancer
Worldwide, hepatocellular cancer (HCC) is the 
second leading cause of cancer-related death in men [46]. 
Although the multi-targeted small molecule tyrosine 
kinase inhibitor sorafenib is approved for the treatment 
of advanced HCC [67], OS remains less than a year [23]. 
Significantly, BRD4 is overexpressed in human HCC 
tumors, and treatment with JQ1 decreases proliferation 
of HCC cell lines and primary cells isolated from human 
HCC tumors [68]. JQ1 also blocks growth of HCC tumors 
in xenograft mouse models [68]. In HCC cells, JQ1 
induces cell cycle arrest primarily through decreasing 
c-MYC expression and increasing expression of p27 [68], 
along with induction of apoptosis through upregulation of 
the pro-apoptotic gene BIM [68]. Overall, these findings 
suggest that BET proteins may be potential therapeutic 
targets in the treatment of HCC.
bet inhibitors and brain tumors
treatment of glioblastoma
Glioblastoma (GBM) is the most common primary 
brain cancer in adults with a median OS of 15-17 months 
and a 5-year survival of less than 5% [69, 70]. GBM 
has been classified into different subgroups based upon 
complex genetic and signaling aberrations [71, 72], 
and BET inhibitors have been shown to have efficacy 
in a range of GBM models reflecting these different 
subgroups [73, 74]. JQ1 decreased proliferation of both 
CD133+ GBM stem cells and non-stem cancer cells while 
promoting apoptosis, decreasing c-MYC and BCL-XL 
levels, and increasing p21 levels [73]. JQ1 also blocked 
GBM progression in an orthotopic tumor model [73].
BET inhibitors have also been evaluated in GBM 
tumors with aberrant EGFR signaling [74]. EGFR is 
mutated or amplified in > 50% of GBM tumors [71], with 
the EGFRvIII mutation resulting in ligand-independent 
activation of EGFR signaling [75]. Significantly, 
EGFRvIII sensitizes GBM cells to JQ1, with JQ1 inducing 
apoptosis and suppressing EGFRvIII-dependent tumor 
growth in vitro and in xenograft orthotopic mouse model 
[74]. Mechanistically, in GBM cells EGFRvIII induces 
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SOX9 and FOXG1, which in turn collaborate to activate 
an oncogenic gene regulatory program [74]. SOX9 and 
FOXG1 also regulate expression of BRD4 with subsequent 
regulation of c-MYC expression to promote tumor growth 
[74]. Together, these results suggest that BET inhibitors 
may have efficacy in GBM, particularly GBM patients 
whose tumors harbor an EGFRvIII mutation.
treatment of medulloblastoma
Medulloblastoma is the most common malignant 
brain tumor of childhood [76]. Transcriptional profiling 
studies have identified four distinct molecular subgroups 
of medulloblastoma: Wnt, Sonic hedgehog (Shh), Group 
3, and Group 4 [77]. Group 3 medulloblastoma is often 
associated with amplification of c-MYC and has the worst 
overall prognosis, with 5-year OS rates of only 50% [76, 
77]. Notably, several studies have shown that JQ1 has 
efficacy in c-MYC-amplified medulloblastoma [78-80]. 
Treatment with JQ1 decreased c-MYC expression and 
inhibited c-MYC-associated transcriptional targets [78-
80]. JQ1 also suppressed stem cell-associated signaling 
in medulloblastoma cells and inhibited medulloblastoma 
tumor cell self-renewal [80]. Furthermore, JQ1 treatment 
reduced tumor growth and prolonged survival in mice 
harboring medulloblastoma xenografts [78-80].
BET inhibitors have also been found to be effective 
against the Shh subgroup of medulloblastoma [76]. In 
canonical Hedgehog (Hh) signaling, Hh ligands bind to 
the cell-surface receptor Patched, triggering a Smoothened 
(SMO)-dependent signaling cascade that results in 
activation of GLI transcription factors and transactivation 
of Hh target genes [81]. While SMO inhibitors have 
shown efficacy against medulloblastoma [82, 83], tumors 
eventually develop resistance to SMO inhibitors [84, 85]. 
Recently, studies identified that BRD4 directly occupies 
GLI1 and GLI2 promoters, and the BET inhibitors JQ1 
and I-BET151 decreased expression of GLI1, GLI2 
and GLI-target genes in medulloblastom [86, 87]. JQ1 
inhibited cell viability and proliferation in SMO-inhibitor 
resistant Hh-driven medulloblastoma cell lines [86], while 
BET inhibitors also decreased Hh-driven medulloblastoma 
in xenograft mouse models [86, 87]. Together, these results 
suggest that BET inhibitors may be effective in both Shh 
and Group 3 medulloblastomas.
PotentIAl toxIcItIes of bet 
InhIbItors
Silencing of BRD4 in transgenic mouse models 
suggests that treatment with potent BET inhibitors will 
likely have clinical toxicities [88]. Sustained BRD4 
knockdown was found to induce epithelial hyperplasia 
and follicular skin defects that were rapidly reversed 
when BRD4 was restored in the mouse model [88]. BRD4 
knockdown also caused loss of multiple cell types in the 
intestine, including a reduction in the number of functional 
stem cells [88]. Similarly, treatment of wild-type mice with 
a small molecule BET inhibitor suppressed intestinal stem 
cell differentiation [89]. However, the intestinal changes 
were reversible in both the BRD4 knockdown experiments 
and the BET inhibitor mouse studies, suggesting that these 
potential toxicities could be managed with appropriate 
dose scheduling on a human clinical trial. 
Mouse studies have also suggested that BET 
inhibitors may exacerbate toxicities seen with concurrent 
radiation and chemotherapy treatment [88, 89]. Transgenic 
mice with BRD4 knockdown were more likely to 
develop radiation damage to the intestines, with delay 
in repair and recovery of normal bowel function [88]. In 
addition, mice treated with a BET inhibitor demonstrated 
increased apoptosis in the intestine when co-treated with 
gemcitabine [89]. BET inhibition has also been shown 
to exacerbate colitis in mice treated with dextran sodium 
sulfate [90]. There is clearly potential for synergistic 
toxicities when BET inhibitors are combined with other 
therapies, and this will have to be carefully considered 
during clinical trial design. However, these synergistic 
effects were also reversible [88, 89], further emphasizing 
the importance of clinical trial design for BET inhibitors 
used in combination studies.
mechAnIsms of resIstAnce to bet 
InhIbItors
As the effectiveness of targeted therapies can 
be limited by de novo resistance or by subsequent 
development of resistance [91], there has been increasing 
interest in characterizing mechanisms of resistance 
to BET inhibitors. This is particularly important as a 
better understanding of the mechanisms of resistance 
may identify which patients and types of cancers should 
be treated with BET inhibitors, and may allow for 
identification of additional therapeutic targets that may 
extend the efficacy of BET inhibitors. However, until 
recently little was known about the mechanisms by which 
cancer cells developed resistance to BET inhibitors.
re-expression of mYc
We have shown that pancreatic cancer cells 
developing resistance to JQ1 were also resistant to other 
BET inhibitors and to BRD4 down regulation [92]. Our 
work demonstrated that the JQ1-resistant cells upregulated 
c-MYC through increased binding of GLI2 to the c-MYC 
promoter, allowing continued cell growth in 3D collagen. 
Significantly, targeting GLI2 re-sensitized pancreatic 
cancer cells to BET inhibitors and BRD4 down regulation 
[92]. Consistent with our findings, leukemia cells have 
also been shown to upregulate c-MYC levels during the 
development of resistance to BET inhibitors [93, 94]. 
Resistant cells also appeared to contribute to expansion 
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of the leukemia stem cell population [93]. Transcriptional 
profiling of the resistant cells demonstrated activation 
of the WNT transcriptional program, thus facilitating 
c-MYC re-expression [93, 94]. Notably, WNT-β-catenin 
signaling has previously been shown to be important for 
cancer stem cell maintenance [95], and blocking WNT 
targets in this model not only re-sensitized the leukemia 
cells to JQ1 but also led to re-suppression of c-MYC [93, 
94]. Activation of the WNT pathway in leukemia cells in 
vivo was also found to drive de novo resistance to BET 
inhibition [93]. Together, these results demonstrate that in 
some models, resistant cells continue to rely on c-MYC 
to drive proliferation, but in the face of BET inhibition, 
resistant cells will shift from BRD4-mediated expression 
of MYC expression to alternative pathways, including 
GLI2 or WNT-β-catenin signaling, in order to maintain 
MYC levels. 
bromodomain-independent role of brd4
In contrast to the resistance mechanism identified in 
pancreatic cancer and leukemia cells [92-94], TNBC cells 
developing resistance to BET inhibitors continue to rely 
on BRD4 for ongoing proliferation [39]. Resistant cells 
remain sensitive to BRD4 knockdown, suggesting that 
resistant cells activate a bromodomain-independent role of 
BRD4 with subsequent recruitment of BRD4 to enhancers 
[39]. Resistant cells also demonstrate increased binding of 
BRD4 to MED1 in a bromodomain-independent manner 
that is unaffected by BET inhibitors [39]. Finally, resistant 
cells demonstrate hyperphosphorylation of BRD4 as a 
result of decreased activity of the phosphatase PP2A and 
resulting in increased binding of BRD4 to MED1 [39].
Activation of alternative signaling pathways
Using a whole-genome shRNA screen of 77 breast 
cancer cell lines to identify cancer drivers, BRD4 was 
identified as a potential target in luminal breast cancer 
[96]. Luminal/HER2+ cells were more sensitive to BRD4 
knockdown than basal breast cancers [96]. Clinically, 
luminal breast cancer cells are typically ER+/PR+, [97] 
while basal breast cancer cells are usually triple-negative 
[37, 98]. Surprisingly, many of the luminal/HER2+ 
breast cancer cell lines that were sensitive to BRD4 
knockdown were subsequently found to be resistant to JQ1 
treatment, suggesting that BRD4 also has a bromodomain-
independent role in this cell type [96]. Intriguingly, a 
strong correlation was seen between JQ1 resistance and 
concurrent PIK3CA mutation. Overexpression of PI3KCA 
in sensitive breast cancer cells conferred resistance to 
JQ1, while treatment with a PI3KCA inhibitor sensitized 
resistant cells to JQ1 [96]. Using mTOR inhibitors to 
block downstream PI3K signaling sensitized resistant cells 
to JQ1 in vitro and in vivo [96]. Conversely, combining 
BET inhibitors with PI3K inhibitors can sustain PI3K 
inhibition and enhance cell-killing [99]. Significantly, 
BET inhibitors can also enhance the therapeutic benefit of 
mTOR inhibitors in breast cancer cells [32]. Overall, these 
results suggest that targeting PI3K/mTOR signaling may 
help sensitize JQ1-resistant cells to BET inhibitors.
conclusIons
A growing body of research has now demonstrated 
that BET inhibitors have a significant anti-tumor effect 
in a range of solid tumors and represent an exciting new 
avenue of targeting tumor growth through modulation 
of transcriptional programming. Some tumors, including 
triple negative breast cancer and small cell lung cancer 
[39, 53], are particularly sensitive to BET inhibitors. 
Patients with these tumors may be ideal candidates for 
BET inhibitor trials, and several ongoing studies are 
actively enrolling patients with these particular cancers 
(Table 2). In addition, BET inhibitors may also have a 
role in preventing or overcoming acquired resistance to 
targeted therapies in patients whose treatment options 
currently include FDA-approved therapies [10, 32, 36, 44, 
99]. Moving forward, it will be important to determine 
whether BET inhibitors can extend response to lapatinib 
in breast cancer patients or to enzalutamide in prostate 
cancer patients. For many tumors, effective use of BET 
inhibitors will likely require a combination approach with 
other targeted and epigenetic therapies, and this in turn 
will require careful analysis of trial design and dosing 
schedules to minimize overlapping toxicities. Finally, 
as we further elucidate the resistance mechanisms that 
govern the overall response to BET inhibitors [39, 92-
94], targeting these resistance pathways will provide new 
opportunities to further increase the clinical efficacy of 
BET inhibitors. 
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